Biotech · Private company
MedImmune LLC
Track this companyFree. Adds MedImmune LLC to your Dealase workspace and tells you when its record changes.
Clinical trials258 recruiting or active
Pipeline programs35From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline35
- AZD4635Phase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Metastatic Microsatellite-stable Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · Stage III Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · Metastatic Microsatellite-stable Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 2 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Durvalumab + MonalizumabPhase 2 · Stage III Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Durvalumab + OleclumabPhase 2 · Stage III Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- FOLFOXPhase 2 · Metastatic Microsatellite-stable Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Folinic acidPhase 2 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 2 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFOX6Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MonalizumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Nab-paclitaxelPhase 2 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- OleclumabPhase 2 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- OleclumabPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- OleclumabPhase 2 · Metastatic Microsatellite-stable Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- OsimertinibPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 2 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TremelimumabPhase 2 · Unresectable Pleural or Peritoneal Malignant MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- TremelimumabPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AxitinibPhase 1 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Selected Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- DurvalumabPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- LenvatinibPhase 1 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- MEDI1191Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MEDI5752Phase 1 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- MEDI5752Phase 1 · Selected Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Paclitaxel or Nab-PaclitaxelPhase 1 · Selected Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Selected Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 1 · Selected Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 5, 2020ClinicalTrials.gov NCT04522323 · fetched Nov 12, 2026
- COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 13, 2019ClinicalTrials.gov NCT04068610 · fetched Nov 12, 2026
- Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care TherapyPHASE1 · TERMINATED · started Jul 23, 2019ClinicalTrials.gov NCT03199040 · fetched Nov 12, 2026
- A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid TumorsPHASE1 · COMPLETED · started May 8, 2019ClinicalTrials.gov NCT03946800 · fetched Nov 12, 2026
- Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 MetabolismPHASE2 · TERMINATED · started Jan 31, 2019ClinicalTrials.gov NCT03773172 · fetched Nov 12, 2026
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCPHASE2 · COMPLETED · started Dec 19, 2018ClinicalTrials.gov NCT03822351 · fetched Nov 12, 2026
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Nov 26, 2018ClinicalTrials.gov NCT03693612 · fetched Nov 12, 2026
- Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaPHASE1_PHASE2 · TERMINATED · started Aug 8, 2018ClinicalTrials.gov NCT03376659 · fetched Nov 12, 2026
- Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or MelanomaPHASE1 · COMPLETED · started Jul 25, 2018ClinicalTrials.gov NCT03336606 · fetched Nov 12, 2026
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.PHASE1_PHASE2 · COMPLETED · started Jun 21, 2018ClinicalTrials.gov NCT03611556 · fetched Nov 12, 2026
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 8, 2018ClinicalTrials.gov NCT03381274 · fetched Nov 12, 2026
- A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 24, 2018ClinicalTrials.gov NCT03530397 · fetched Nov 12, 2026
- Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)COMPLETED · started Feb 27, 2018ClinicalTrials.gov NCT03373045 · fetched Nov 12, 2026
- RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Jul 10, 2017ClinicalTrials.gov NCT03215095 · fetched Nov 12, 2026
- Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid TumorsPHASE2 · TERMINATED · started Dec 1, 2016ClinicalTrials.gov NCT02938793 · fetched Nov 12, 2026
- A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune DiseasesPHASE1 · COMPLETED · started Aug 26, 2016ClinicalTrials.gov NCT02780674 · fetched Nov 12, 2026
- Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma SubtypesPHASE2 · COMPLETED · started Aug 16, 2016ClinicalTrials.gov NCT02815995 · fetched Nov 12, 2026
- A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 22, 2016ClinicalTrials.gov NCT02671435 · fetched Nov 12, 2026
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 19, 2015ClinicalTrials.gov NCT02519348 · fetched Nov 12, 2026
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckPHASE1_PHASE2 · COMPLETED · started Aug 6, 2015ClinicalTrials.gov NCT02499328 · fetched Nov 12, 2026
- Anti-OX40 Antibody in Head and Neck Cancer PatientsPHASE1 · COMPLETED · started Nov 12, 2014ClinicalTrials.gov NCT02274155 · fetched Nov 12, 2026
- Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)PHASE1 · TERMINATED · started Dec 17, 2013ClinicalTrials.gov NCT01891981 · fetched Nov 12, 2026
- A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of AgeTERMINATED · started Dec 2, 2013ClinicalTrials.gov NCT01997450 · fetched Nov 12, 2026
- Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing RadiotherapyCOMPLETED · started Nov 11, 2013ClinicalTrials.gov NCT02153151 · fetched Nov 12, 2026
- Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant MesotheliomaPHASE2 · ACTIVE_NOT_RECRUITING · started May 17, 2013ClinicalTrials.gov NCT01843374 · fetched Nov 12, 2026